Drugs / ASP5878
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02038673 | Nov 2013 → Jul 2017 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP5878 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02038673 ↗ |
| Action | Inhibit | “ASP5878 (orally available novel small-molecule FGFR 1,2,3 and 4 inhibitor” NCT02038673 ↗ |
| Modality | Small molecule | “ASP5878 (orally available novel small-molecule FGFR 1,2,3 and 4 inhibitor” NCT02038673 ↗ |
| Route | Oral | “oral ASP5878” NCT02038673 ↗ |